XML 39 R28.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2019

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2019 and December 31, 2018:

		March 31, 2019
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted-Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent		$	31,951			$	(10,983	)		$	20,968				10.5
Approved hormone therapy drug candidate patents			2,519,316				(322,431	)			2,196,885				13.75
Hormone therapy drug candidate patents (pending)			1,967,124				—				1,967,124				n/a
Non-amortizable intangible assets:
Multiple trademarks			270,753				—				270,753				indefinite
Total		$	4,789,144			$	(333,414	)		$	4,455,730

		December 31, 2018
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted-Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent		$	31,951			$	(10,484	)		$	21,467				10.75
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			2,234,129				(282,485	)			1,951,644				14
Hormone therapy drug candidate patents (pending)			1,855,279				—				1,855,279				n/a
Non-amortizable intangible assets:
Multiple trademarks			264,289				—				264,289				indefinite
Total		$	4,477,391			$	(384,712	)		$	4,092,679

Schedule of estimated amortization expense

Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:

Year Ending December 31,			Estimated Amortization
2019 (9 months)			$	121,333
2020			$	161,777
2021			$	161,777
2022			$	161,777
2023			$	161,777